Floatz logo

ROPIVACAINE

Degenerative Disc Disease

Johns Hopkins UniversitySmall moleculeN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
89/ 100

Competitive context

6 Active assets in the Degenerative Disc Disease cohort.

Asset / SponsorPhaseRating
NEPENTHE
Brigham and Women's Hospital
Phase 4BB
Oxycodone
Brigham and Women's Hospital
Phase 4BB
Rexlemestrocel-L
Mesoblast, Ltd.
Phase 3BB
AUTOLOGOUS CONDITIONED PLASMA
Allmed Medical Center
Phase 2BB
Single Dose Mpcs
Mesoblast, Ltd.
Phase 2B

View all 11 →

Same molecule, other indications

ROPIVACAINE is also rated in:

post-operative pain, non-human animalDormant
BBB
Indicative ·
76 / 100
View asset →
Knee Pain ChronicDormant
BBB
Indicative ·
76 / 100
View asset →
osteoarthritis, hipDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →